Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma

Clinical Science

Volumn 126, Issue 3, 2014, Pages 243-252

  De Bethlenfalva Hora, Caroline Erös ^a   Mertens, Joachim C ^b,c   Piguet, Anne Christine ^a   Kettenbach, Joachim ^d   Schmitt, Johannes ^b   Terracciano, Luigi ^e   Weimann, Rosemarie ^f   Dufour, Jean François ^a   Geier, Andreas ^a,b,g  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Liver; Multifocal hepatocellular carcinoma; Non targeted tumour; Radiofrequency ablation; Sorafenib; Tumour growth

Indexed keywords

BAY 54 9085; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 10; SCATTER FACTOR; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GROWTH; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SHAM PROCEDURE; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; HEPATOCYTE GROWTH FACTOR; INTERLEUKIN-10; LIVER NEOPLASMS, EXPERIMENTAL; MACROPHAGES; NIACINAMIDE; PHENYLUREA COMPOUNDS; RATS; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84885923397     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130089     Document Type: Article

References (43)

1. El-Serag, H. B. and Rudolph, K. L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576
2. Sherman, M. (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25, 143-154
3. Llovet, J. M., Burroughs, A. and Bruix, J. (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917
4. Poon, R. T. (2008) Is radiofrequency ablation the treatment of choice for patients with small hepatocellular carcinoma? Nat. Clin. Pract. 5, 492-493
5. Kudo, M. (2010) Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology 78 (Suppl. 1), 113-124
6. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A. et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390
7. Motzer, R. J. and Bukowski, R. M. (2006) Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24, 5601-5608
8. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M. et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109
9. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M. and Lynch, M. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140
10. Nikfarjam, M., Muralidharan, V. and Christophi, C. (2006) Altered growth patterns of colorectal liver metastases after thermal ablation. Surgery 139, 73-81
11. Mertens, J. C., Martin, I. V., Schmitt, J., Frei, P., Bruners, P., Herweg, C., Mahnken, A. H., Mullhaupt, B. and Geier, A. (2011) Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals. Eur. J. Radiol. 81, 1601-1606
12. Yang, R., Rescorla, F. J., Reilly, C. R., Faught, P. R., Sanghvi, N. T., Lumeng, L., Franklin, Jr, T. D. and Grosfeld, J. L. (1992) A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation. J. Surg. Res. 52, 193-198
13. Semela, D., Piguet, A. C., Kolev, M., Schmitter, K., Hlushchuk, R., Djonov, V., Stoupis, C. and Dufour, J. F. (2007) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol. 46, 840-848
14. Piguet, A. C., Saar, B., Hlushchuk, R., St-Pierre, M. V., McSheehy, P. M., Radojevic, V., Afthinos, M., Terracciano, L., Djonov, V. and Dufour, J. F. (2011) Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol. Cancer Ther. 10, 1007-1017
15. Semela, D. and Dufour, J. F. (2004) Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864-880
16. Hora, C., Romanque, P. and Dufour, J. F. (2011) Effect of sorafenib on murine liver regeneration. Hepatology 53, 577-586
17. Saranadasa, M. and Wang, E. S. (2011) Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. Cytokine 53, 115-129
18. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F. and Aaronson, S. A. (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802-804
19. Suzuki, K., Hayashi, N., Yamada, Y., Yoshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A. et al. (1994) Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20, 1231-1236
20. Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. and Okamoto, E. (1997) Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25, 619-623
21. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V. and Ferrara, N. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3_-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343
22. LeCouter, J., Moritz, D. R., Li, B., Phillips, G. L., Liang, X. H., Gerber, H. P., Hillan, K. J. and Ferrara, N. (2003) Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299, 890-893
23. Reiberger, T., Angermayr, B., Schwabl, P., Rohr-Udilova, N., Mitterhauser, M., Gangl, A. and Peck-Radosavljevic, M. (2009) Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J. Hepatol. 51, 865-873
24. Desar, I. M., Jacobs, J. F. M., Hulsbergen-vandeKaa, C. A., Oyen, W. J., Mulders, P. F., van der Graaf, W. T., Adema, G. J., van Herpen, C. M. and de Vries, I. J. (2011) Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer 129, 507-512
25. Cao, M., Xu, Y., Youn, J. I., Cabrera, R., Zhang, X., Gabrilovich, D., Nelson, D. R. and Liu, C. (2011) Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab. Invest. 91, 598-608
26. Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H. and Brossart, P. (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111, 5610-5620
27. Evrard, S., Menetrier-Caux, C., Biota, C., Neaud, V., Mathoulin-Pelissier, S., Blay, J. Y. and Rosenbaum, J. (2007) Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases. Gastroenterol. Clin. Biol. 31, 141-145
28. Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A. and Comoglio, P. M. (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629-641
29. Nakamura, Y., Morishita, R., Nakamura, S., Aoki, M., Moriguchi, A., Matsumoto, K., Nakamura, T., Higaki, J. and Ogihara, T. (1996) A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension 28, 409-413
30. Mazzone, M., Basilico, C., Cavassa, S., Pennacchietti, S., Risio, M., Naldini, L., Comoglio, P. M. and Michieli, P. (2004) An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J. Clin. Invest. 114, 1418-1432
31. Haen, S. P., Pereira, P. L., Salih, H. R., Rammensee, H. G. and Gouttefangeas, C. (2011) More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin. Dev. Immunol. 2011, 160250
32. Mellman, I., Coukos, G. and Dranoff, G. (2011) Cancer immunotherapy comes of age. Nature 480, 480-489
33. Zerbini, A., Pilli, M., Fagnoni, F., Pelosi, G., Pizzi, M. G., Schivazappa, S., Laccabue, D., Cavallo, C., Schianchi, C., Ferrari, C. and Missale, G. (2008) Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J. Immunother. 31, 271-282
34. Sauter, B., Albert, M. L., Francisco, L., Larsson, M., Somersan, S. and Bhardwaj, N. (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423-434
35. den Brok, M. H., Sutmuller, R. P., van der Voort, R., Bennink, E. J., Figdor, C. G., Ruers, T. J. and Adema, G. J. (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 64, 4024-4029
36. Zerbini, A., Pilli, M., Penna, A., Pelosi, G., Schianchi, C., Molinari, A., Schivazappa, S., Zibera, C., Fagnoni, F. F., Ferrari, C. and Missale, G. (2006) Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 66, 1139-1146
37. Ali, M. Y., Grimm, C. F., Ritter, M., Mohr, L., Allgaier, H. P., Weth, R., Bocher, W. O., Endrulat, K., Blum, H. E. and Geissler, M. (2005) Activation of dendritic cells by local ablation of hepatocellular carcinoma. J. Hepatol. 43, 817-822
38. Zerbini, A., Pilli, M., Laccabue, D., Pelosi, G., Molinari, A., Negri, E., Cerioni, S., Fagnoni, F., Soliani, P., Ferrari, C. and Missale, G. (2010) Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 138, 1931-1942
39. Welsh, T. J., Green, R. H., Richardson, D., Waller, D. A., O'Byrne, K. J. and Bradding, P. (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 23, 8959-8967
40. Mocellin, S., Marincola, F. M. and Young, H. A. (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukocyte Biol. 78, 1043-1051
41. Lu, C., Soria, J. C., Tang, X., Xu, X. C., Wang, L., Mao, L., Lotan, R., Kemp, B., Bekele, B. N., Feng, L. et al. (2004) Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J. Clin. Oncol. 22, 4575-4583
42. Adris, S., Klein, S., Jasnis, M., Chuluyan, E., Ledda, M., Bravo, A., Carbone, C., Chernajovsky, Y. and Podhajcer, O. (1999) IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther. 6, 1705-1712
43. Gerard, C. M., Bruyns, C., Delvaux, A., Baudson, N., Dargent, J. L., Goldman, M. and Velu, T. (1996) Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum. Gene Ther. 7, 23-31